German drugmaker BioNTech on Wednesday introduced that the European Union will purchase a further 200 million doses of its Coronavirus vaccine, that can be delivered within the second quarter of 2021.
“We will initiate production at our Marburg facility this month and have strengthened our manufacturing network with additional partners. We are continuing to evaluate, together with governments, authorities, and partners at all levels, how we might address an even higher future supply requirement for our vaccines,” stated Dr. Ugur Sahin, the co-founder of BioNTech.
He added that together with US drugmaker Pfizer, they’ve taken further steps to spice up their manufacturing capability in Europe.
“This afternoon, I will be signing a second EU Commission contract with BioNTech/Pfizer for up to an additional 300 million COVID-19 vaccine doses,” the bloc’s well being chief Stella Kyriakides tweeted on Wednesday.
The new settlement between Pfizer/BioNTech and the European Commission brings whole provide to the EU to 500 million doses, with an choice for a further 100 million doses.
This afternoon, I can be signing a second @EU_Commission contract with @BioNTech_Group/@pfizer for as much as a further 300 million #COVID19 vaccine doses. This follows up on our 8 January settlement reached with the corporate.
— Stella Kyriakides (@SKyriakidesEU) February 17, 2021